Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis

Conclusions Hepatic JAK2/ARHGEF1/ROCK expression is associated with portal hypertension and decompensation in human cirrhosis. The deletion of Jak2 in myofibroblasts attenuated experimental fibrosis and acute inhibition of JAK2 decreased PP. Thus, JAK2 inhibitors, already in clinical use for other indications, might be a new approach to treat cirrhosis with portal hypertension.

http://gut.bmj.com/cgi/content/short/66/1/145?rss=1

Source: Gut - December 6, 2016 Category: Gastroenterology Authors: Klein, S., Rick, J., Lehmann, J., Schierwagen, R., Schierwagen, I. G., Verbeke, L., Hittatiya, K., Uschner, F. E., Manekeller, S., Strassburg, C. P., Wagner, K.-U., Sayeski, P. P., Wolf, D., Laleman, W., Sauerbruch, T., Trebicka, J. Tags: Cirrhosis, Pancreas and biliary tract, Gastrointestinal hormones Hepatology Source Type: research